<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00770</drugbank-id>
  <drugbank-id>APRD00785</drugbank-id>
  <name>Alprostadil</name>
  <description>Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.</description>
  <cas-number>745-65-3</cas-number>
  <unii>F5TD010360</unii>
  <average-mass>354.487</average-mass>
  <monoisotopic-mass>354.240624195</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.</indication>
  <pharmacodynamics>Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora.&amp;nbsp;As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops.&amp;nbsp;This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.</pharmacodynamics>
  <mechanism-of-action>Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This is because, as a form of prostaglandinE1 (PGE1) it has multiple effects on blood flow. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea.</mechanism-of-action>
  <toxicity>Oral, mouse: LD&lt;sub&gt;50&lt;/sub&gt; = 186 mg/kg; Oral, rat: LD&lt;sub&gt;50&lt;/sub&gt; = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.</toxicity>
  <metabolism>Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by beta- and omega-oxidation.</metabolism>
  <absorption>The absolute bioavailability of alprostadil has not been determined.</absorption>
  <half-life>5 to 10 minutes (after a single dose), in healthy adults and neonates.</half-life>
  <protein-binding>Bound in plasma primarily to albumin (81% bound) and to a lesser extent alpha-globulin IV-4 fraction (55% bound).</protein-binding>
  <route-of-elimination>Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by β- and ω-oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">(11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid</synonym>
    <synonym language="english" coder="">(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate</synonym>
    <synonym language="english" coder="">11α,15α-dihydroxy-9-oxo-13-trans-prostenoic acid</synonym>
    <synonym language="english/spanish/french" coder="inn/usan">Alprostadil</synonym>
    <synonym language="latin" coder="inn">Alprostadilum</synonym>
    <synonym language="english" coder="">PGE-1</synonym>
    <synonym language="english" coder="">PGE1</synonym>
    <synonym language="english" coder="">Prostaglandin E1</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alprostadil</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-04</started-marketing-on>
      <ended-marketing-on>2009-07-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravascular; Intravenous</route>
      <fda-application-number>ANDA074815</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alprostadil</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-04</started-marketing-on>
      <ended-marketing-on>2009-05-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravascular; Intravenous</route>
      <fda-application-number>ANDA074815</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alprostadil</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-1501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravascular</route>
      <fda-application-number>ANDA075196</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alprostadil Injection USP</name>
      <labeller>Advanced Dosage Forms Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02285282</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravascular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alprostadil Injection, USP</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02241680</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-10-26</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intra-arterial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caverject</name>
      <labeller>Pharmacia and Upjohn Company</labeller>
      <ndc-id/>
      <ndc-product-code>0009-5131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-06</started-marketing-on>
      <ended-marketing-on>2009-08-25</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>5.4 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject</name>
      <labeller>Pharmacia and Upjohn Company</labeller>
      <ndc-id/>
      <ndc-product-code>0009-3778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-06</started-marketing-on>
      <ended-marketing-on>2009-08-25</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10.5 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject</name>
      <labeller>Pharmacia and Upjohn Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0009-3701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20.5 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject</name>
      <labeller>Pharmacia and Upjohn Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0009-7686</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>41.1 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject Impulse</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-28</started-marketing-on>
      <ended-marketing-on>2008-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20 ug/0.5mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA021212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject Impulse</name>
      <labeller>U.S. Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63539-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 ug/0.5mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA021212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject Impulse</name>
      <labeller>U.S. Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63539-221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20 ug/0.5mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA021212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject Impulse</name>
      <labeller>Pharmacia and Upjohn Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0009-5181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 ug/0.5mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA021212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject Impulse</name>
      <labeller>Pharmacia and Upjohn Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0009-5182</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20 ug/0.5mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA021212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caverject Sterile Powder - Kit 11.9mcg /vial</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215748</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-30</started-marketing-on>
      <ended-marketing-on>2006-08-02</ended-marketing-on>
      <dosage-form>Kit; Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intracavernous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caverject Sterile Powder - Kit 23.2mcg/vial</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215756</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intracavernous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caverject Sterile Powder - Pws 11.9mcg/vial</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215179</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-30</started-marketing-on>
      <ended-marketing-on>2006-08-02</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intracavernous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caverject Sterile Powder - Pws 23.2mcg/vial</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215187</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intracavernous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Edex</name>
      <labeller>Auxilium Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66887-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on>2015-10-01</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Edex</name>
      <labeller>Auxilium Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66887-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on>2015-10-01</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Edex</name>
      <labeller>Auxilium Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66887-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on>2015-10-01</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>40 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Edex</name>
      <labeller>Endo Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52244-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Edex</name>
      <labeller>Endo Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52244-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Edex</name>
      <labeller>Endo Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52244-040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>40 ug/1mL</strength>
      <route>Intracavernous</route>
      <fda-application-number>NDA020649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>VIVUS, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62541-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-19</started-marketing-on>
      <ended-marketing-on>2012-03-31</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength>125 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>VIVUS, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62541-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-19</started-marketing-on>
      <ended-marketing-on>2012-04-30</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength>250 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>VIVUS, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62541-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-19</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength>500 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>VIVUS, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62541-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-19</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength>1000 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>MEDA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0037-8110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>125 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>MEDA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0037-8120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>250 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>MEDA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0037-8130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>500 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>MEDA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0037-8140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>1000 ug/1</strength>
      <route>Urethral</route>
      <fda-application-number>NDA020700</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238593</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>250 mcg</strength>
      <route>Urethral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238594</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>500 mcg</strength>
      <route>Urethral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238595</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>1000 mcg</strength>
      <route>Urethral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Muse</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238592</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength>125 mcg</strength>
      <route>Urethral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Prostin Vr Pediatric</name>
      <labeller>Pharmacia &amp; Upjohn Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0009-3169</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravascular; Intravenous</route>
      <fda-application-number>NDA018484</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prostin Vr Sterile Solution</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00559253</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intra-arterial; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vitaros</name>
      <labeller>Bgp Pharma Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359413</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vitaros</name>
      <labeller>Bgp Pharma Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359421</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Alista</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Alprostan</name>
      <company>Zentiva</company>
    </international-brand>
    <international-brand>
      <name>Alprostapint</name>
      <company>Closter</company>
    </international-brand>
    <international-brand>
      <name>Alprostar</name>
      <company>Recordati</company>
    </international-brand>
    <international-brand>
      <name>Alprostin</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Alprox-TD</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Altesil</name>
      <company>Taiyo Pharmaceutical</company>
    </international-brand>
    <international-brand>
      <name>Alyprost</name>
      <company>Fuji Yakuhin</company>
    </international-brand>
    <international-brand>
      <name>Apistandin</name>
      <company>Fuji Yakuhin</company>
    </international-brand>
    <international-brand>
      <name>Aplicav</name>
      <company>Libbs</company>
    </international-brand>
    <international-brand>
      <name>Befar</name>
      <company>Nexmed</company>
    </international-brand>
    <international-brand>
      <name>Bolesi</name>
      <company>Yaoyou Pharmaceutical</company>
    </international-brand>
    <international-brand>
      <name>Bondil</name>
      <company>Meda</company>
    </international-brand>
    <international-brand>
      <name>Cardiobron</name>
      <company>Fada</company>
    </international-brand>
    <international-brand>
      <name>Caverject DC</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Caverject Dual</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Eglandin</name>
      <company>Welfide</company>
    </international-brand>
    <international-brand>
      <name>Femprox</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Kai Tong</name>
      <company>Jilin Yuhua Pharmaceutical Co.</company>
    </international-brand>
    <international-brand>
      <name>Kaishi</name>
      <company>Tide Pharmaceutical</company>
    </international-brand>
    <international-brand>
      <name>Karon</name>
      <company>Zentiva</company>
    </international-brand>
    <international-brand>
      <name>Liple</name>
      <company>Tanabe Mitsubishi Pharma</company>
    </international-brand>
    <international-brand>
      <name>Minprog</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Palux</name>
      <company>Taisho Yakuhin</company>
    </international-brand>
    <international-brand>
      <name>Pridax</name>
      <company>Gebro</company>
    </international-brand>
    <international-brand>
      <name>Prink</name>
      <company>Taiyo Pharmaceutical</company>
    </international-brand>
    <international-brand>
      <name>Prolisina VR</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Prostandin</name>
      <company>Ono Yakuhin</company>
    </international-brand>
    <international-brand>
      <name>Prostavasin</name>
      <company>Schwarz</company>
    </international-brand>
    <international-brand>
      <name>Prostin VR</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Prostivas</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Sugiran</name>
      <company>Esteve</company>
    </international-brand>
    <international-brand>
      <name>Tandetron</name>
      <company>Takata Seiyaku</company>
    </international-brand>
    <international-brand>
      <name>Topiglan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vasaprostan</name>
      <company>Bayer</company>
    </international-brand>
    <international-brand>
      <name>Vasoprost</name>
      <company>UCB</company>
    </international-brand>
    <international-brand>
      <name>Vasostenoon</name>
      <company>Kevelt</company>
    </international-brand>
    <international-brand>
      <name>Viridal</name>
      <company>UCB</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Caverject Sterile Powder - Kit 23.2mcg/vial</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Sterile Powder - Kit 11.9mcg /vial</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Impulse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Alprostadil</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Alprostadil</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Edex</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Edex</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Edex</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Prostin Vr Pediatric</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Impulse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Impulse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Edex</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Edex</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Edex</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Alprostadil</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Impulse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Impulse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Prostin Vr Sterile Solution</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Sterile Powder - Pws 11.9mcg/vial</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Muse</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Vitaros</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Vitaros</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Caverject Sterile Powder - Pws 23.2mcg/vial</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Alprostadil Injection USP</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
    <mixture>
      <name>Alprostadil Injection, USP</name>
      <ingredients>Alprostadil</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bedford Labs</name>
      <url>http://www.bedfordlabs.com</url>
    </packager>
    <packager>
      <name>Ben Venue Laboratories Inc.</name>
      <url>http://www.benvenue.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Nutrimol De Mexico Sa De Cv</name>
      <url/>
    </packager>
    <packager>
      <name>Paladin Laboratories Usa Inc.</name>
      <url>http://www.paladin-labs.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Schwarz Pharma Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Sicor Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
      <url>http://www.vetter-pharma.com</url>
    </packager>
    <packager>
      <name>Vivus</name>
      <url>http://www.vivus.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="true" url="">Bedford laboratories div ben venue laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Teva parenteral medicines inc</manufacturer>
    <manufacturer generic="false" url="http://www.pfizer.com/">Pfizer inc</manufacturer>
    <manufacturer generic="false" url="">Pharmacia and upjohn co</manufacturer>
    <manufacturer generic="false" url="">Schwarz pharma ag</manufacturer>
    <manufacturer generic="false" url="">Vivus inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Muse 125 mcg urethral suppository</description>
      <cost currency="USD">29.39</cost>
      <unit>suppository</unit>
    </price>
    <price>
      <description>Muse 125 mcg Pellets</description>
      <cost currency="USD">30.56</cost>
      <unit>pellet</unit>
    </price>
    <price>
      <description>Muse 250 mcg urethral suppository</description>
      <cost currency="USD">30.76</cost>
      <unit>suppository</unit>
    </price>
    <price>
      <description>Muse 250 mcg Pellets</description>
      <cost currency="USD">31.99</cost>
      <unit>pellet</unit>
    </price>
    <price>
      <description>Muse 500 mcg urethral suppository</description>
      <cost currency="USD">32.92</cost>
      <unit>suppository</unit>
    </price>
    <price>
      <description>Muse 500 mcg Pellets</description>
      <cost currency="USD">34.23</cost>
      <unit>pellet</unit>
    </price>
    <price>
      <description>Muse 1000 mcg urethral suppository</description>
      <cost currency="USD">35.54</cost>
      <unit>suppository</unit>
    </price>
    <price>
      <description>Caverject impulse 10 mcg kit</description>
      <cost currency="USD">36.23</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Muse 1000 mcg Pellets</description>
      <cost currency="USD">36.97</cost>
      <unit>pellet</unit>
    </price>
    <price>
      <description>Caverject Impulse 1 Box = 2 Blister Trays, 10 mcg</description>
      <cost currency="USD">37.51</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Caverject impulse 20 mcg kit</description>
      <cost currency="USD">46.66</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Caverject Impulse 1 Box = 2 Blister Trays, 20 mcg</description>
      <cost currency="USD">47.77</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Alprostadil 500 mcg/ml vial</description>
      <cost currency="USD">66.0</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Edex 10 mcg cartridge kit</description>
      <cost currency="USD">74.88</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Edex Cartridge 2 Pack 10 mcg Kit Box</description>
      <cost currency="USD">77.22</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Edex 20 mcg cartridge kit</description>
      <cost currency="USD">96.47</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Edex 2 Pack 20 mcg Kit Box</description>
      <cost currency="USD">97.47</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Prostin vr 500 mcg/ml ampul</description>
      <cost currency="USD">108.0</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Edex 40 mcg cartridge kit</description>
      <cost currency="USD">132.18</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Edex Cartridge 2 Pack 40 mcg Kit Box</description>
      <cost currency="USD">135.23</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Edex Cartridge 6 Pack 10 mcg Kit Box</description>
      <cost currency="USD">233.65</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Prostin Vr 500 mcg/ml</description>
      <cost currency="USD">266.72</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Caverject 6 20 mcg Solution, 1 Box Contains 6 Vials Box</description>
      <cost currency="USD">272.05</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Edex 6 Pack 20 mcg Kit Box</description>
      <cost currency="USD">301.0</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Caverject 6 40 mcg Solution Box</description>
      <cost currency="USD">341.78</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Edex Cartridge 6 Pack 40 mcg Kit Box</description>
      <cost currency="USD">412.4</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Alprostadil powder</description>
      <cost currency="USD">5049.0</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Autacoids</category>
      <mesh-id>D012898</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Cardiac Therapy</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Drugs Used in Erectile Dysfunction</category>
      <mesh-id/>
    </category>
    <category>
      <category>Eicosanoids</category>
      <mesh-id>D015777</mesh-id>
    </category>
    <category>
      <category>Fatty Acids</category>
      <mesh-id>D005227</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Monounsaturated</category>
      <mesh-id>D005229</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Unsaturated</category>
      <mesh-id>D005231</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Genitourinary Arterial Vasodilation</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Inflammation Mediators</category>
      <mesh-id>D018836</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Miscellaneous Vasodilatating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>OAT1/SLC22A6 inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>OAT1/SLC22A6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>OAT3/SLC22A8 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Prostaglandin E1 Agonist</category>
      <mesh-id/>
    </category>
    <category>
      <category>Prostaglandin Receptor Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Prostaglandins</category>
      <mesh-id>D011453</mesh-id>
    </category>
    <category>
      <category>Prostaglandins E</category>
      <mesh-id>D011458</mesh-id>
    </category>
    <category>
      <category>Prostaglandins, Synthetic</category>
      <mesh-id>D011465</mesh-id>
    </category>
    <category>
      <category>Urological Agents</category>
      <mesh-id>D064804</mesh-id>
    </category>
    <category>
      <category>Urologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vasodilating Agents</category>
      <mesh-id>D014665</mesh-id>
    </category>
    <category>
      <category>Venous Vasodilation</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravascular; Intravenous</route>
      <strength>500 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravascular</route>
      <strength>500 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravascular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intra-arterial; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>10.5 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>20.5 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>41.1 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>5.4 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>10 ug/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>20 ug/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Kit; liquid; powder, for solution</form>
      <route>Intracavernous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; liquid; powder, for solution</form>
      <route>Intracavernous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intracavernous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>10 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>20 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intracavernous</route>
      <strength>40 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>1000 ug/1</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>1000 mcg</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>125 ug/1</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>125 mcg</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>250 mcg</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>250 ug/1</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>500 ug/1</strength>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Urethral</route>
      <strength>500 mcg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravascular; Intravenous</route>
      <strength>500 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intra-arterial; Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C01EA01">
      <level code="C01EA">Prostaglandins</level>
      <level code="C01E">OTHER CARDIAC PREPARATIONS</level>
      <level code="C01">CARDIAC THERAPY</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="G04BE01">
      <level code="G04BE">Drugs used in erectile dysfunction</level>
      <level code="G04B">UROLOGICALS</level>
      <level code="G04">UROLOGICALS</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:12.92</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>3whx</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00770.pdf?1265922797</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00770.pdf?1265922737</msds>
  <patents>
    <patent>
      <number>5773020</number>
      <country>United States</country>
      <approved>1998-06-30</approved>
      <expires>2010-04-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1335346</number>
      <country>Canada</country>
      <approved>1995-04-25</approved>
      <expires>2012-04-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5886039</number>
      <country>United States</country>
      <approved>1999-03-23</approved>
      <expires>2016-03-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of hypotension and priapism can be increased when Sildenafil is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>The risk or severity of hypotension and priapism can be increased when Milrinone is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of hypotension and priapism can be increased when Anagrelide is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The risk or severity of hypotension and priapism can be increased when Theophylline is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of hypotension and priapism can be increased when Pentoxifylline is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>The risk or severity of hypotension and priapism can be increased when Tadalafil is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The risk or severity of hypotension and priapism can be increased when Vardenafil is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of hypotension and priapism can be increased when Ibudilast is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06237</drugbank-id>
      <name>Avanafil</name>
      <description>The risk or severity of hypotension and priapism can be increased when Avanafil is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06267</drugbank-id>
      <name>Udenafil</name>
      <description>The risk or severity of hypotension and priapism can be increased when Udenafil is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The risk or severity of hypotension and priapism can be increased when Doxofylline is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11792</drugbank-id>
      <name>Mirodenafil</name>
      <description>The risk or severity of hypotension and priapism can be increased when Mirodenafil is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>The risk or severity of hypotension and priapism can be increased when Fostamatinib is combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00168</drugbank-id>
      <name>Aspartame</name>
      <description>The excretion of Alprostadil can be decreased when combined with Aspartame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Pravastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The excretion of Alprostadil can be decreased when combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefotiam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The excretion of Alprostadil can be decreased when combined with Conjugated estrogens.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00345</drugbank-id>
      <name>Aminohippuric acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Aminohippuric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The excretion of Alprostadil can be decreased when combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefalotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The excretion of Alprostadil can be decreased when combined with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefotaxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00536</drugbank-id>
      <name>Guanidine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Guanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The excretion of Alprostadil can be decreased when combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The excretion of Alprostadil can be decreased when combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cephalexin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The excretion of Alprostadil can be decreased when combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The excretion of Alprostadil can be decreased when combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The excretion of Alprostadil can be decreased when combined with Oxytetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00650</drugbank-id>
      <name>Leucovorin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Leucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The excretion of Alprostadil can be decreased when combined with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The excretion of Alprostadil can be decreased when combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The excretion of Alprostadil can be decreased when combined with Acyclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefaclor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Dinoprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Famotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ganciclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The excretion of Alprostadil can be decreased when combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01051</drugbank-id>
      <name>Novobiocin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Novobiocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01053</drugbank-id>
      <name>Benzylpenicillin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Benzylpenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Melatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefadroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefamandole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefazolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ceftizoxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefacetrile.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ceftibuten.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The excretion of Alprostadil can be decreased when combined with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01597</drugbank-id>
      <name>Cilastatin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cilastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01606</drugbank-id>
      <name>Tazobactam</name>
      <description>The excretion of Alprostadil can be decreased when combined with Tazobactam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01650</drugbank-id>
      <name>trans-2-hydroxycinnamic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with trans-2-hydroxycinnamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>The excretion of Alprostadil can be decreased when combined with Topiroxostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03553</drugbank-id>
      <name>Glutaric Acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Glutaric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03793</drugbank-id>
      <name>Benzoic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Benzoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Taurocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04519</drugbank-id>
      <name>Caprylic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Caprylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05016</drugbank-id>
      <name>Ataluren</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ataluren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The excretion of Alprostadil can be decreased when combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The excretion of Alprostadil can be decreased when combined with Dolutegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefaloridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The excretion of Alprostadil can be decreased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11751</drugbank-id>
      <name>Cabotegravir</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cabotegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The excretion of Alprostadil can be decreased when combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The excretion of Alprostadil can be decreased when combined with Avatrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The excretion of Alprostadil can be decreased when combined with Letermovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The excretion of Alprostadil can be decreased when combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12866</drugbank-id>
      <name>Pradigastat</name>
      <description>The excretion of Alprostadil can be decreased when combined with Pradigastat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The excretion of Alprostadil can be decreased when combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The excretion of Alprostadil can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>The therapeutic efficacy of Alprostadil can be decreased when used in combination with Patent Blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The excretion of Alprostadil can be increased when combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>The excretion of Alprostadil can be increased when combined with Methyltestosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The excretion of Alprostadil can be increased when combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The excretion of Alprostadil can be increased when combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The excretion of Alprostadil can be increased when combined with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00140</drugbank-id>
      <name>Riboflavin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Riboflavin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Folic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The excretion of Alprostadil can be decreased when combined with Doxycycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ethoxzolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Codeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Piperacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cidofovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ceftazidime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The excretion of Alprostadil can be decreased when combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The excretion of Alprostadil can be decreased when combined with Foscarnet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00578</drugbank-id>
      <name>Carbenicillin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Carbenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The excretion of Alprostadil can be decreased when combined with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The excretion of Alprostadil can be decreased when combined with Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>The excretion of Alprostadil can be decreased when combined with Fluorescein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The excretion of Alprostadil can be decreased when combined with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>The excretion of Alprostadil can be decreased when combined with Adefovir dipivoxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The excretion of Alprostadil can be decreased when combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00155</drugbank-id>
      <name>Citrulline</name>
      <description>The excretion of Citrulline can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The excretion of Tenofovir disoproxil can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The excretion of Grepafloxacin can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>The excretion of Cefdinir can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The excretion of Stavudine can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The excretion of Lamivudine can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The excretion of Ranitidine can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>The excretion of Didanosine can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00943</drugbank-id>
      <name>Zalcitabine</name>
      <description>The excretion of Zalcitabine can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The excretion of Levofloxacin can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The excretion of Captopril can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02527</drugbank-id>
      <name>Cyclic adenosine monophosphate</name>
      <description>The excretion of Cyclic adenosine monophosphate can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08846</drugbank-id>
      <name>Ellagic acid</name>
      <description>The excretion of Ellagic acid can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The excretion of Silibinin can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The excretion of Tenofovir alafenamide can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12243</drugbank-id>
      <name>Edaravone</name>
      <description>The excretion of Edaravone can be decreased when combined with Alprostadil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The excretion of Alprostadil can be decreased when combined with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Gentamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The excretion of Alprostadil can be decreased when combined with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The excretion of Alprostadil can be decreased when combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Amoxicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Streptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The excretion of Alprostadil can be decreased when combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01147</drugbank-id>
      <name>Cloxacillin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Cefradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The excretion of Alprostadil can be decreased when combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02266</drugbank-id>
      <name>Flufenamic acid</name>
      <description>The excretion of Alprostadil can be decreased when combined with Flufenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The excretion of Alprostadil can be decreased when combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The excretion of Alprostadil can be decreased when combined with Phenacetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The excretion of Alprostadil can be decreased when combined with Istradefylline.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.04</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.88e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>mifepristone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>354.487</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>354.240624195</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H34O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>GMVPRGQOIOIIMI-DWKJAMRDSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>94.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>98.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>42.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-1.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>26.7 mg/L</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>115-116 °C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.20</value>
      <source>AVDEEF,A ET AL. (1995)</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>4.85 (at 25 °C)</value>
      <source>AVDEEF,A ET AL. (1995)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7335</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>15544</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>149351</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508029</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C04741</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00180</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4444306</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50101853</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448334</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>XPG</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001490</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>1882</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>1882</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alprostadil</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL495</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/alprostadil.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cav1073.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/alprostadil.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000368</id>
      <name>Prostaglandin E2 receptor EP2 subtype</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5603</ref-id>
            <pubmed-id>10509658</pubmed-id>
            <citation>Dijkstra BG, Schneemann A, Hoyng PF: Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.</citation>
          </article>
          <article>
            <ref-id>A5604</ref-id>
            <pubmed-id>15840408</pubmed-id>
            <citation>Takahashi HK, Iwagaki H, Tamura R, Katsuno G, Xue D, Sugita S, Mori S, Yoshino T, Tanaka N, Nishibori M: Differential effect of prostaglandins E1 and E2 on lipopolysaccharide-induced adhesion molecule expression on human monocytes. Eur J Pharmacol. 2005 Apr 11;512(2-3):223-30.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P43116" source="Swiss-Prot">
        <name>Prostaglandin E2 receptor EP2 subtype</name>
        <general-function>Prostaglandin e receptor activity</general-function>
        <specific-function>Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle.</specific-function>
        <gene-name>PTGER2</gene-name>
        <locus>14q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>24-47
66-91
112-132
152-176
199-223
263-286
300-323</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.19</theoretical-pi>
        <molecular-weight>39759.945</molecular-weight>
        <chromosome-location>14</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9594</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGER2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U19487</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>632650</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>341</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>341</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43116</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PE2R2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PGE receptor EP2 subtype</synonym>
          <synonym>Prostanoid EP2 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010263|Prostaglandin E2 receptor EP2 subtype
MGNASNDSQSEDCETRQWLPPGESPAISSVMFSAGVLGNLIALALLARRWRGDVGCSAGR
RSSLSLFHVLVTELVFTDLLGTCLISPVVLASYARNQTLVALAPESRACTYFAFAMTFFS
LATMLMLFAMALERYLSIGHPYFYQRRVSRSGGLAVLPVIYAVSLLFCSLPLLDYGQYVQ
YCPGTWCFIRHGRTAYLQLYATLLLLLIVSVLACNFSVILNLIRMHRRSRRSRCGPSLGS
GRGGPGARRRGERVSMAEETDHLILLAIMTITFAVCSLPFTIFAYMNETSSRKEKWDLQA
LRFLSINSIIDPWVFAILRPPVLRLMRSVLCCRISLRTQDATQTSCSTQSDASKQADL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010264|Prostaglandin E2 receptor EP2 subtype (PTGER2)
ATGGGCAATGCCTCCAATGACTCCCAGTCTGAGGACTGCGAGACGCGACAGTGGCTTCCC
CCAGGCGAAAGCCCAGCCATCAGCTCCGTCATGTTCTCGGCCGGGGTGCTGGGGAACCTC
ATAGCACTGGCGCTGCTGGCGCGCCGCTGGCGGGGGGACGTGGGGTGCAGCGCCGGCCGC
AGGAGCTCCCTCTCCTTGTTCCACGTGCTGGTGACCGAGCTGGTGTTCACCGACCTGCTC
GGGACCTGCCTCATCAGCCCAGTGGTACTGGCTTCGTACGCGCGGAACCAGACCCTGGTG
GCACTGGCGCCCGAGAGCCGCGCGTGCACCTACTTCGCTTTCGCCATGACCTTCTTCAGC
CTGGCCACGATGCTCATGCTCTTCGCCATGGCCCTGGAGCGCTACCTCTCGATCGGGCAC
CCCTACTTCTACCAGCGCCGCGTCTCGCGCTCCGGGGGCCTGGCCGTGCTGCCTGTCATC
TATGCAGTCTCCCTGCTCTTCTGCTCGCTGCCGCTGCTGGACTATGGGCAGTACGTCCAG
TACTGCCCCGGGACCTGGTGCTTCATCCGGCACGGGCGGACCGCTTACCTGCAGCTGTAC
GCCACCCTGCTGCTGCTTCTCATTGTCTCGGTGCTCGCCTGCAACTTCAGTGTCATTCTC
AACCTCATCCGCATGCACCGCCGAAGCCGGAGAAGCCGCTGCGGACCTTCCCTGGGCAGT
GGCCGGGGCGGCCCCGGGGCCCGCAGGAGAGGGGAAAGGGTGTCCATGGCGGAGGAGACG
GACCACCTCATTCTCCTGGCTATCATGACCATCACCTTCGCCGTCTGCTCCTTGCCTTTC
ACGATTTTTGCATATATGAATGAAACCTCTTCCCGAAAGGAAAAATGGGACCTCCAAGCT
CTTAGGTTTTTATCAATTAATTCAATAATTGACCCTTGGGTCTTTGCCATCCTTAGGCCT
CCTGTTCTGAGACTAATGCGTTCAGTCCTCTGTTGTCGGATTTCATTAAGAACACAAGAT
GCAACACAAACTTCCTGTTCTACACAGTCAGATGCCAGTAAACAGGCTGACCTTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin E receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin E stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000064</id>
      <name>Prostaglandin E2 receptor EP1 subtype</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10832</ref-id>
            <pubmed-id>15560119</pubmed-id>
            <citation>Norel X, de Montpreville V, Brink C: Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 2004 Oct;74(1-4):101-12.</citation>
          </article>
          <article>
            <ref-id>A10833</ref-id>
            <pubmed-id>14561849</pubmed-id>
            <citation>Takahashi HK, Iwagaki H, Tamura R, Xue D, Sano M, Mori S, Yoshino T, Tanaka N, Nishibori M: Unique regulation profile of prostaglandin e1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther. 2003 Dec;307(3):1188-95. Epub 2003 Oct 15.</citation>
          </article>
          <article>
            <ref-id>A10834</ref-id>
            <pubmed-id>10670413</pubmed-id>
            <citation>Ito Y, Murai Y, Ishibashi H, Onoue H, Akaike N: The prostaglandin E series modulates high-voltage-activated calcium channels probably through the EP3 receptor in rat paratracheal ganglia. Neuropharmacology. 2000 Jan 4;39(2):181-90.</citation>
          </article>
          <article>
            <ref-id>A10835</ref-id>
            <pubmed-id>16516814</pubmed-id>
            <citation>Matlhagela K, Taub M: Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins Other Lipid Mediat. 2006 Mar;79(1-2):101-13. Epub 2006 Jan 27.</citation>
          </article>
          <article>
            <ref-id>A10836</ref-id>
            <pubmed-id>11524243</pubmed-id>
            <citation>Tokuda H, Kozawa O, Miwa M, Uematsu T: p38 mitogen-activated protein (MAP) kinase but not p44/p42 MAP kinase is involved in prostaglandin E1-induced vascular endothelial growth factor synthesis in osteoblasts. J Endocrinol. 2001 Sep;170(3):629-38.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P34995" source="Swiss-Prot">
        <name>Prostaglandin E2 receptor EP1 subtype</name>
        <general-function>Prostaglandin e receptor activity</general-function>
        <specific-function>Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.</specific-function>
        <gene-name>PTGER1</gene-name>
        <locus>19p13.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>36-62
73-96
112-133
156-177
202-227
295-321
333-354</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>12.22</theoretical-pi>
        <molecular-weight>41800.655</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGER1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L22647</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>410209</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>340</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>340</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P34995</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PE2R1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PGE receptor EP1 subtype</synonym>
          <synonym>Prostanoid EP1 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000128|Prostaglandin E2 receptor EP1 subtype
MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSNLLALALLAQA
AGRLRRRRSAATFLLFVASLLATDLAGHVIPGALVLRLYTAGRAPAGGACHFLGGCMVFF
GLCPLLLGCGMAVERCVGVTRPLLHAARVSVARARLALAAVAAVALAVALLPLARVGRYE
LQYPGTWCFIGLGPPGGWRQALLAGLFASLGLVALLAALVCNTLSGLALLRARWRRRSRR
PPPASGPDSRRRWGAHGPRSASASSASSIASASTFFGGSRSSGSARRARAHDVEMVGQLV
GIMVVSCICWSPMLVLVALAVGGWSSTSLQRPLFLAVRLASWNQILDPWVYILLRQAVLR
QLLRLLPPRAGAKGGPAGLGLTPSAWEASSLRSSRHSGLSHF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018915|Prostaglandin E2 receptor EP1 subtype (PTGER1)
ATGAGCCCTTGCGGGCCCCTCAACCTGAGCCTGGCGGGCGAGGCGACCACATGCGCGGCG
CCCTGGGTCCCCAACACGTCGGCCGTGCCGCCGTCGGGCGCTTCGCCCGCGCTGCCCATC
TTCTCCATGACGCTGGGCGCCGTGTCCAACCTGCTGGCGCTGGCGCTGCTGGCGCAGGCC
GCGGGCCGCCTGCGACGCCGCCGCTCGGCCGCCACCTTCCTGCTGTTCGTGGCCAGCCTG
CTGGCCACCGACCTGGCGGGCCACGTGATCCCGGGCGCGCTGGTGCTGCGTCTGTACACT
GCGGGGCGCGCTCCGGCCGGCGGGGCCTGCCACTTCCTGGGCGGCTGCATGGTCTTCTTC
GGCCTGTGCCCGCTGCTGCTGGGCTGTGGCATGGCCGTGGAGCGCTGCGTGGGCGTCACG
CGGCCGCTGCTCCACGCCGCGCGGGTCTCGGTCGCCCGCGCGCGCCTGGCGCTGGCCGCG
GTGGCCGCGGTGGCCTTGGCCGTGGCGCTGCTGCCGCTGGCGCGCGTGGGCCGCTATGAG
CTGCAGTACCCGGGCACGTGGTGCTTCATCGGCCTGGGTCCCCCGGGCGGCTGGCGCCAG
GCACTGCTTGCTGGCCTCTTCGCCAGCCTCGGCCTGGTCGCGCTCCTCGCCGCGCTGGTG
TGCAACACGCTCAGCGGCCTGGCCCTGCTACGCGCCCGCTGGCGACGCCGCTCCCGACGG
CCTCCCCCGGCCTCAGGCCCCGACAGCCGGCGTCGCTGGGGGGCGCACGGACCCCGCTCG
GCCTCCGCCTCGTCCGCCTCGTCCATCGCTTCGGCCTCCACCTTCTTTGGCGGCTCTCGG
AGCAGCGGCTCGGCACGCAGAGCTCGCGCCCACGACGTGGAGATGGTGGGCCAGCTTGTC
GGTATCATGGTGGTGTCGTGCATCTGCTGGAGCCCAATGCTGGTGTTGGTGGCGCTGGCC
GTCGGCGGCTGGAGCTCTACCTCCCTGCAGCGGCCACTGTTCCTGGCCGTGCGCCTTGCC
TCCTGGAACCAGATCCTGGACCCTTGGGTGTACATCCTACTGCGCCAGGCCGTGCTGCGC
CAACTGCTTCGCCTCTTGCCCCCGAGGGCCGGAGCCAAGGGCGGCCCCGCGGGGCTGGGC
CTAACACCGAGCGCCTGGGAGGCCAGCTCGCTGCGCAGCTCCCGGCACAGCGGCCTCAGC
CACTTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin E receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0003561</id>
      <name>Prostaglandin D2 receptor 2</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A20292</ref-id>
            <pubmed-id>9579725</pubmed-id>
            <citation>Wright DH, Metters KM, Abramovitz M, Ford-Hutchinson AW: Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y5Y4" source="Swiss-Prot">
        <name>Prostaglandin D2 receptor 2</name>
        <general-function>Prostaglandin j receptor activity</general-function>
        <specific-function>Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Receptor activation is responsible, at least in part, in immune regulation and allergic/inflammation responses.</specific-function>
        <gene-name>PTGDR2</gene-name>
        <locus>11q12-q13.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>34-56
68-89
107-127
147-168
211-231
248-269
289-308</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.95</theoretical-pi>
        <molecular-weight>43267.15</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4502</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB008535</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4204216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>339</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y5Y4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PD2R2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Chemoattractant receptor-homologous molecule expressed on Th2 cells</synonym>
          <synonym>CRTH2</synonym>
          <synonym>DL1R</synonym>
          <synonym>G-protein coupled receptor 44</synonym>
          <synonym>GPR44</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037246|Prostaglandin D2 receptor 2
MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVENGVILFVVGCR
MRQTVVTTWVLHLALSDLLASASLPFFTYFLAVGHSWELGTTFCKLHSSIFFLNMFASGF
LLSAISLDRCLQVVRPVWAQNHRTVAAAHKVCLVLWALAVLNTVPYFVFRDTISRLDGRI
MCYYNVLLLNPGPDRDATCNSRQVALAVSKFLLAFLVPLAIIASSHAAVSLRLQHRGRRR
PGRFVRLVAAVVAAFALCWGPYHVFSLLEARAHANPGLRPLVWRGLPFVTSLAFFNSVAN
PVLYVLTCPDMLRKLRRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARSASPLALCSRP
EEPRGPARLLGWLLGSCAASPQTGPLNRALSSTSS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017141|Prostaglandin D2 receptor 2 (PTGDR2)
ATGTCGGCCAACGCCACACTGAAGCCACTCTGCCCCATCCTGGAGCAGATGAGCCGTCTC
CAGAGCCACAGCAACACCAGCATCCGCTACATCGACCACGCGGCCGTGCTGCTGCACGGG
CTGGCCTCGCTGCTGGGCCTGGTGGAGAATGGAGTCATCCTCTTCGTGGTGGGCTGCCGC
ATGCGCCAGACCGTGGTCACCACCTGGGTGCTGCACCTGGCGCTGTCCGACCTGTTGGCC
TCTGCTTCCCTGCCCTTCTTCACCTACTTCTTGGCCGTGGGCCACTCGTGGGAGCTGGGC
ACCACCTTCTGCAAACTGCACTCCTCCATCTTCTTTCTCAACATGTTCGCCAGCGGCTTC
CTGCTCAGCGCCATCAGCCTGGACCGCTGCCTGCAGGTGGTGCGGCCGGTGTGGGCGCAG
AACCACCGCACCGTGGCCGCGGCGCACAAAGTCTGCCTGGTGCTTTGGGCACTAGCGGTG
CTCAACACGGTGCCCTATTTCGTGTTCCGGGACACCATCTCGCGGCTGGACGGGCGCATT
ATGTGCTACTACAATGTGCTGCTCCTGAACCCGGGGCCTGACCGCGATGCCACGTGCAAC
TCGCGGCAGGTGGCCCTGGCCGTCAGCAAGTTCCTGCTGGCCTTCCTGGTGCCGCTGGCG
ATCATCGCCTCGAGCCACGCGGCCGTGAGCCTGCGGTTGCAGCACCGCGGCCGCCGGCGG
CCAGGCCGCTTCGTGCGCCTGGTGGCGGCCGTCGTGGCCGCCTTCGCGCTCTGCTGGGGG
CCCTACCACGTGTTCAGCCTGCTGGAGGCGCGGGCGCACGCAAACCCGGGGCTGCGGCCG
CTCGTGTGGCGCGGGCTGCCCTTCGTCACCAGCCTGGCCTTCTTCAACAGCGTGGCCAAC
CCGGTGCTCTACGTGCTCACCTGCCCCGACATGCTGCGCAAGCTGCGGCGCTCGCTGCGC
ACGGTGCTGGAGAGCGTGCTGGTGGACGACAGCGAGCTGGGTGGCGCGGGAAGCAGCCGC
CGCCGCCGCACCTCCTCCACCGCCCGCTCGGCCTCCCCTTTAGCTCTCTGCAGCCGCCCG
GAGGAACCGCGGGGCCCCGCGCGTCTCCTCGGCTGGCTGCTGGGCAGCTGCGCAGCGTCC
CCGCAGACGGGCCCCCTGAACCGGGCGCTGAGCAGCACCTCGAGTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin D receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin F receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin J receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of male germ cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0003639</id>
      <name>Multidrug resistance-associated protein 5</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16091</ref-id>
            <pubmed-id>12835412</pubmed-id>
            <citation>Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15440" source="Swiss-Prot">
        <name>Multidrug resistance-associated protein 5</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>Acts as a multispecific organic anion pump which can transport nucleotide analogs.</specific-function>
        <gene-name>ABCC5</gene-name>
        <locus>3q27</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>179-199
219-239
296-316
317-337
400-420
434-454
608-628
848-868
917-937
997-1017
1018-1038
1104-1124
1127-1147</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.89</theoretical-pi>
        <molecular-weight>160658.8</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:56</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF104942</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4140698</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>783</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15440</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 5</synonym>
          <synonym>MOAT-C</synonym>
          <synonym>MRP5</synonym>
          <synonym>Multi-specific organic anion transporter C</synonym>
          <synonym>pABC11</synonym>
          <synonym>SMRP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006995|Multidrug resistance-associated protein 5
MKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRTRPLECQDALETAARAEGLS
LDASMHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQHPVDNAGLFSCMTFSWLSSLAR
VAHKKGELSMEDVWSLSKHESSDVNCRRLERLWQEELNEVGPDAASLRRVVWIFCRTRLI
LSIVCLMITQLAGFSGPAFMVKHLLEYTQATESNLQYSLLLVLGLLLTEIVRSWSLALTW
ALNYRTGVRLRGAILTMAFKKILKLKNIKEKSLGELINICSNDGQRMFEAAAVGSLLAGG
PVVAILGMIYNVIILGPTGFLGSAVFILFYPAMMFASRLTAYFRRKCVAATDERVQKMNE
VLTYIKFIKMYAWVKAFSQSVQKIREEERRILEKAGYFQSITVGVAPIVVVIASVVTFSV
HMTLGFDLTAAQAFTVVTVFNSMTFALKVTPFSVKSLSEASVAVDRFKSLFLMEEVHMIK
NKPASPHIKIEMKNATLAWDSSHSSIQNSPKLTPKMKKDKRASRGKKEKVRQLQRTEHQA
VLAEQKGHLLLDSDERPSPEEEEGKHIHLGHLRLQRTLHSIDLEIQEGKLVGICGSVGSG
KTSLISAILGQMTLLEGSIAISGTFAYVAQQAWILNATLRDNILFGKEYDEERYNSVLNS
CCLRPDLAILPSSDLTEIGERGANLSGGQRQRISLARALYSDRSIYILDDPLSALDAHVG
NHIFNSAIRKHLKSKTVLFVTHQLQYLVDCDEVIFMKEGCITERGTHEELMNLNGDYATI
FNNLLLGETPPVEINSKKETSGSQKKSQDKGPKTGSVKKEKAVKPEEGQLVQLEEKGQGS
VPWSVYGVYIQAAGGPLAFLVIMALFMLNVGSTAFSTWWLSYWIKQGSGNTTVTRGNETS
VSDSMKDNPHMQYYASIYALSMAVMLILKAIRGVVFVKGTLRASSRLHDELFRRILRSPM
KFFDTTPTGRILNRFSKDMDEVDVRLPFQAEMFIQNVILVFFCVGMIAGVFPWFLVAVGP
LVILFSVLHIVSRVLIRELKRLDNITQSPFLSHITSSIQGLATIHAYNKGQEFLHRYQEL
LDDNQAPFFLFTCAMRWLAVRLDLISIALITTTGLMIVLMHGQIPPAYAGLAISYAVQLT
GLFQFTVRLASETEARFTSVERINHYIKTLSLEAPARIKNKAPSPDWPQEGEVTFENAEM
RYRENLPLVLKKVSFTIKPKEKIGIVGRTGSGKSSLGMALFRLVELSGGCIKIDGVRISD
IGLADLRSKLSIIPQEPVLFSGTVRSNLDPFNQYTEDQIWDALERTHMKECIAQLPLKLE
SEVMENGDNFSVGERQLLCIARALLRHCKILILDEATAAMDTETDLLIQETIREAFADCT
MLTIAHRLHTVLGSDRIMVLAQGQVVEFDTPSVLLSNDSSRFYAMFAAAENKVAVKG</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012531|Multidrug resistance-associated protein 5 (ABCC5)
ATGAAGGATATCGACATAGGAAAAGAGTATATCATCCCCAGTCCTGGGTATAGAAGTGTG
AGGGAGAGAACCAGCACTTCTGGGACGCACAGAGACCGTGAAGATTCCAAGTTCAGGAGA
ACTCGACCGTTGGAATGCCAAGATGCCTTGGAAACAGCAGCCCGAGCCGAGGGCCTCTCT
CTTGATGCCTCCATGCATTCTCAGCTCAGAATCCTGGATGAGGAGCATCCCAAGGGAAAG
TACCATCATGGCTTGAGTGCTCTGAAGCCCATCCGGACTACTTCCAAACACCAGCACCCA
GTGGACAATGCTGGGCTTTTTTCCTGTATGACTTTTTCGTGGCTTTCTTCTCTGGCCCGT
GTGGCCCACAAGAAGGGGGAGCTCTCAATGGAAGACGTGTGGTCTCTGTCCAAGCACGAG
TCTTCTGACGTGAACTGCAGAAGACTAGAGAGACTGTGGCAAGAAGAGCTGAATGAAGTT
GGGCCAGACGCTGCTTCCCTGCGAAGGGTTGTGTGGATCTTCTGCCGCACCAGGCTCATC
CTGTCCATCGTGTGCCTGATGATCACGCAGCTGGCTGGCTTCAGTGGACCAAATTTTCAG
GATGGCTGTATTCTGCGGTCAGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carbohydrate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycosaminoglycan metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyaluronan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyaluronan metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0001042</id>
      <name>Solute carrier organic anion transporter family member 2B1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16115</ref-id>
            <pubmed-id>10973807</pubmed-id>
            <citation>Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O94956" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 2B1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.</specific-function>
        <gene-name>SLCO2B1</gene-name>
        <locus>11q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>50-69
89-109
116-140
186-215
235-255
274-298
367-388
409-432
437-460
565-587
597-622
656-673</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.39</theoretical-pi>
        <molecular-weight>76709.98</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10962</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLCO2B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB026256</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5006263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O94956</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO2B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>KIAA0880</synonym>
          <synonym>OATP-B</synonym>
          <synonym>OATP-RP2</synonym>
          <synonym>OATP2B1</synonym>
          <synonym>OATPB</synonym>
          <synonym>OATPRP2</synonym>
          <synonym>Organic anion transporter B</synonym>
          <synonym>Organic anion transporter polypeptide-related protein 2</synonym>
          <synonym>SLC21A9</synonym>
          <synonym>Solute carrier family 21 member 9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037115|Solute carrier organic anion transporter family member 2B1
MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKLFVLCHSLLQL
AQLMISGYLKSSISTVEKRFGLSSQTSGLLASFNEVGNTALIVFVSYFGSRVHRPRMIGY
GAILVALAGLLMTLPHFISEPYRYDNTSPEDMPQDFKASLCLPTTSAPASAPSNGNCSSY
TETQHLSVVGIMFVAQTLLGVGGVPIQPFGISYIDDFAHNSNSPLYLGILFAVTMMGPGL
AFGLGSLMLRLYVDINQMPEGGISLTIKDPRWVGAWWLGFLIAAGAVALAAIPYFFFPKE
MPKEKRELQFRRKVLAVTDSPARKGKDSPSKQSPGESTKKQDGLVQIAPNLTVIQFIKVF
PRVLLQTLRHPIFLLVVLSQVCLSSMAAGMAIFLPKFLERQFSITASYANLLIGCLSFPS
VIVGIVVGGVLVKRLHLGPVGCGALCLLGMLLCLFFSLPLFFIGCSSHQIAGITHQTSAH
PGLELSPSCMEACSCPLDGFNPVCDPSTRVEYITPCHAGCSSWVVQDALDNSQVFYTNCS
CVVEGNPVLAGSCDSTCSHLVVPFLLLVSLGSALACLTHTPSFMLILRGVKKEDKTLAVG
IQFMFLRILAWMPSPVIHGSAIDTTCVHWALSCGRRAVCRYYNNDLLRNRFIGLQFFFKT
GSVICFALVLAVLRQQDKEARTKESRSSPAVEQQLLVSGPGKKPEDSRV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010728|Solute carrier organic anion transporter family member 2B1 (SLCO2B1)
ATGGGCACAGAAAACACACCTGGAGGCAAAGCCAGCCCAGACCCTCAGGACGTGCGGCCA
AGTGTGTTCCATAACATCAAGCTGTTCGTTCTGTGCCACAGCCTGCTGCAGCTGGCGCAG
CTCATGATCTCCGGCTACCTAAAGAGCTCCATCTCCACAGTGGAGAAGCGCTTCGGCCTC
TCCAGCCAGACGTCGGGGCTGCTGGCCTCCTTCAACGAGGTGGGGAACACAGCCTTGATT
GTGTTTGTGAGCTATTTTGGCAGCCGGGTGCACCGACCCCGAATGATTGGCTATGGGGCT
ATCCTTGTGGCCCTGGCGGGCCTGCTCATGACTCTCCCGCACTTCATCTCGGAGCCATAC
CGCTACGACAACACCAGCCCTGAGGATATGCCACAGGACTTCAAGGCTTCCCTGTGCCTG
CCCACAACCTCGGCCCCAGCCTCGGCCCCCTCCAATGGCAACTGCTCAAGCTACACAGAA
ACCCAGCATCTGAGTGTGGTGGGGATCATGTTCGTGGCACAGACCCTGCTGGGCGTGGGC
GGGGTGCCCATTCAGCCCTTTGGCATCTCCTACATCGATGACTTTGCCCACAACAGCAAC
TCGCCCCTCTACCTCGGGATCCTGTTTGCAGTGACCATGATGGGGCCAGGCCTGGCCTTT
GGGCTGGGCAGCCTCATGCTGCGCCTTTATGTGGACATTAACCAGATGCCAGAAGGTGGT
ATCAGCCTGACCATAAAGGACCCCCGATGGGTGGGTGCCTGGTGGCTGGGTTTCCTCATC
GCTGCCGGTGCAGTGGCCCTGGCTGCCATCCCCTACTTCTTCTTCCCCAAGGAAATGCCC
AAGGAAAAACGTGAGCTTCAGTTTCGGCGAAAGGTCTTAGCAGTCACAGACTCACCTGCC
AGGAAGGGCAAGGACTCTCCCTCTAAGCAGAGCCCTGGGGAGTCCACGAAGAAGCAGGAT
GGCCTAGTCCAGATTGCACCAAACCTGACTGTGATCCAGTTCATTAAAGTCTTCCCCAGG
GTGCTGCTGCAGACCCTACGCCACCCCATCTTCCTGCTGGTGGTCCTGTCCCAGGTATGC
TTGTCATCCATGGCTGCGGGCATGGCCACCTTCCTGCCCAAGTTCCTGGAGCGCCAGTTT
TCCATCACAGCCTCCTACGCCAACCTGCTCATCGGCTGCCTCTCCTTCCCTTCGGTCATC
GTGGGCATCGTGGTGGGTGGCGTCCTGGTCAAGCGGCTCCACCTGGGCCCTGTGGGATGC
GGTGCCCTTTGCCTGCTGGGGATGCTGCTGTGCCTCTTCTTCAGCCTGCCGCTCTTCTTT
ATCGGCTGCTCCAGCCACCAGATTGCGGGCATCACACACCAGACCAGTGCCCACCCTGGG
CTGGAGCTGTCTCCAAGCTGCATGGAGGCCTGCTCCTGCCCATTGGACGGCTTTAACCCT
GTCTGCGACCCCAGCACTCGTGTGGAATACATCACACCCTGCCACGCAGGCTGCTCAAGC
TGGGTGGTCCAGGATGCTCTGGACAACAGCCAGGTTTTCTACACCAACTGCAGCTGCGTG
GTGGAGGGCAACCCCGTGCTGGCAGGATCCTGCGACTCAACGTGCAGCCATCTGGTGGTG
CCCTTCCTGCTCCTGGTCAGCCTGGGCTCGGCCCTGGCCTGTCTCACCCACACACCCTCC
TTCATGCTCATCCTAAGAGGAGTGAAGAAAGAAGACAAGACTTTGGCTGTGGGCATCCAG
TTCATGTTCCTGAGGATTTTGGCCTGGATGCCCAGCCCCGTGATCCACGGCAGCGCCATC
GACACCACCTGTGTGCACTGGGCCCTGAGCTGTGGGCGTCGAGCTGTCTGTCGCTACTAC
AATAATGACCTGCTCCGAAACCGGTTCATCGGCCTCCAGTTCTTCTTCAAAACAGGTTCT
GTGATCTGCTTCGCCTTAGTTTTGGCTGTCCTGAGGCAGCAGGACAAAGAGGCAAGGACC
AAAGAGAGCAGATCCAGCCCTGCCGTAGAGCAGCAATTGCTAGTGTCGGGGCCAGGGAAG
AAGCCAGAGGATTCCCGAGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0003661</id>
      <name>Solute carrier organic anion transporter family member 3A1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16355</ref-id>
            <pubmed-id>14631946</pubmed-id>
            <citation>Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UIG8" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 3A1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).</specific-function>
        <gene-name>SLCO3A1</gene-name>
        <locus>15q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>41-60
80-100
107-131
175-203
223-243
262-286
345-366
387-410
415-438
540-562
572-597
631-648</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.71</theoretical-pi>
        <molecular-weight>76552.135</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10952</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB031050</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>6683741</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UIG8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO3A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OATP-D</synonym>
          <synonym>OATP-RP3</synonym>
          <synonym>OATP3A1</synonym>
          <synonym>OATPD</synonym>
          <synonym>OATPRP3</synonym>
          <synonym>Organic anion transporter polypeptide-related protein 3</synonym>
          <synonym>Organic anion-transporting polypeptide D</synonym>
          <synonym>PGE1 transporter</synonym>
          <synonym>SLC21A11</synonym>
          <synonym>Sodium-independent organic anion transporter D</synonym>
          <synonym>Solute carrier family 21 member 11</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037253|Solute carrier organic anion transporter family member 3A1
MQGKKPGGSSGGGRSGELQGDEAQRNKKKKKKVSCFSNIKIFLVSECALMLAQGTVGAYL
VSVLTTLERRFNLQSADVGVIASSFEIGNLALILFVSYFGARGHRPRLIGCGGIVMALGA
LLSALPEFLTHQYKYEAGEIRWGAEGRDVCAANGSGGDEGPDPDLICRNRTATNMMYLLL
IGAQVLLGIGATPVQPLGVSYIDDHVRRKDSSLYIGILFTMLVFGPACGFILGSFCTKIY
VDAVFIDTSNLDITPDDPRWIGAWWGGFLLCGALLFFSSLLMFGFPQSLPPHSEPAMESE
QAMLSEREYERPKPSNGVLRHPLEPDSSASCFQQLRVIPKVTKHLLSNPVFTCIILAACM
EIAVVAGFAAFLGKYLEQQFNLTTSSANQLLGMTAIPCACLGIFLGGLLVKKLSLSALGA
IRMAMLVNLVSTACYVSFLFLGCDTGPVAGVTVPYGNSTAPGSALDPYSPCNNNCECQTD
SFTPVCGADGITYLSACFAGCNSTNLTGCACLTTVPAENATVVPGKCPSPGCQEAFLTFL
CVMCICSLIGAMAQTPSVIILIRTVSPELKSYALGVLFLLLRLLGFIPPPLIFGAGIDST
CLFWSTFCGEQGACVLYDNVVYRYLYVSIAIALKSFAFILYTTTWQCLRKNYKRYIKNHE
GGLSTSEFFASTLTLDNLGRDPVPANQTHRTKFIYNLEDHEWCENMESVL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017177|Solute carrier organic anion transporter family member 3A1 (SLCO3A1)
ATGCAGGGGAAGAAGCCGGGCGGTTCGTCGGGCGGCGGCCGGAGCGGCGAGCTGCAGGGG
GACGAGGCGCAGAGGAACAAGAAAAAGAAAAAGAAGGTGTCCTGCTTTTCCAACATCAAG
ATCTTCCTGGTGTCCGAGTGCGCCCTGATGCTGGCGCAGGGCACGGTGGGCGCCTACCTG
GTGAGCGTCCTGACCACCCTGGAGCGTAGGTTCAACCTGCAGAGCGCTGACGTGGGTGTG
ATCGCTAGCAGCTTCGAGATCGGGAACCTGGCGCTCATCCTCTTCGTGAGCTACTTCGGG
GCACGCGGGCACCGGCCGCGCCTGATCGGCTGCGGCGGCATCGTCATGGCGCTGGGCGCG
CTGCTGTCGGCGCTGCCCGAGTTCCTGACCCACCAGTACAAGTACGAGGCGGGCGAGATC
CGCTGGGGCGCCGAGGGCCGCGACGTCTGCGCAGCCAACGGCTCGGGCGGCGACGAGGGG
CCCGACCCCGACCTCATCTGCCGCAACCGGACGGCTACCAACATGATGTACTTGCTGCTC
ATTGGGGCCCAGGTGCTCCTGGGCATCGGTGCTACCCCTGTGCAGCCCCTGGGCGTCTCC
TACATCGACGACCACGTGCGGAGGAAGGACTCCTCGCTCTATATAGGAATCCTGTTCACG
ATGCTGGTATTTGGACCAGCCTGCGGGTTTATCCTGGGCTCTTTCTGTACCAAAATCTAC
GTGGATGCGGTCTTCATTGACACAAGTAACCTGGACATCACTCCGGACGACCCCCGCTGG
ATCGGAGCCTGGTGGGGTGGCTTTCTGCTCTGCGGTGCCTTACTCTTCTTCTCTTCCCTC
TTGATGTTTGGGTTTCCACAGTCCCTGCCCCCGCACTCAGAGCCCGCCATGGAAAGCGAG
CAGGCCATGCTCTCCGAAAGAGAATACGAGAGACCCAAGCCCAGCAACGGGGTCCTGAGG
CACCCCCTGGAGCCAGACAGCAGTGCCTCCTGTTTCCAGCAGCTGAGAGTGATCCCGAAG
GTCACCAAGCACCTGCTCTCAAACCCTGTGTTCACCTGCATCATCCTGGCCGCCTGCATG
GAGATTGCAGTGGTGGCTGGCTTCGCTGCCTTTTTGGGGAAGTACCTGGAGCAGCAGTTT
AACCTCACCACCTCTTCTGCCAACCAGCTGCTTGGGATGACTGCGATCCCGTGTGCTTGT
CTGGGTATCTTCCTGGGAGGTCTTTTGGTGAAGAAGCTCAGCCTGTCTGCCCTGGGGGCC
ATTCGGATGGCCATGCTCGTCAACCTGGTGTCCACTGCTTGCTACGTCTCCTTCCTCTTC
CTGGGCTGCGACACTGGCCCTGTGGCTGGGGTTACTGTTCCCTATGGAAACAGCACAGCA
CCTGGCTCAGCCCTGGACCCCTACTCGCCCTGCAATAATAACTGTGAATGCCAAACCGAT
TCCTTCACTCCAGTGTGTGGGGCAGATGGCATCACCTACCTGTCTGCCTGCTTTGCTGGC
TGCAACAGCACGAATCTCACGGGCTGTGCGTGCCTCACCACCGTCCCTGCTGAGAACGCA
ACCGTGGTTCCTGGAAAATGCCCCAGTCCTGGGTGCCAAGAGGCCTTCCTCACTTTCCTC
TGTGTGATGTGTATCTGCAGCCTGATCGGTGCCATGGCACAGACACCCTCAGTCATCATC
CTCATCAGGACAGTCAGCCCTGAACTCAAGTCTTACGCTTTGGGAGTTCTTTTTCTCCTC
CTTCGTTTGTTGGGCTTCATCCCTCCACCCCTCATCTTCGGGGCTGGCATCGACTCCACC
TGCCTGTTCTGGAGCACGTTCTGTGGGGAGCAAGGCGCCTGCGTCCTCTACGACAATGTG
GTCTACCGATACCTGTATGTCAGCATCGCCATCGCGCTCAAATCCTTCGCCTTCATCCTG
TACACCACCACGTGGCAGTGCCTGAGGAAAAACTATAAACGCTACATCAAAAACCACGAG
GGCGGGCTGAGCACCAGCACAGAGTACCAAGACATTGAGACTGAGAAAACCTGCCCCGAA
TCACATTCACCTTCAGAAGACTCCTTTGTGAGAAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0001188</id>
      <name>Multidrug resistance-associated protein 4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16091</ref-id>
            <pubmed-id>12835412</pubmed-id>
            <citation>Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15439" source="Swiss-Prot">
        <name>Multidrug resistance-associated protein 4</name>
        <general-function>Atpase activity, coupled to transmembrane movement of substances</general-function>
        <specific-function>May be an organic anion pump relevant to cellular detoxification.</specific-function>
        <gene-name>ABCC4</gene-name>
        <locus>13q32</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>93-113
136-156
207-227
228-248
328-348
351-371
440-460
710-730
771-791
836-856
858-878
954-974
977-997
1038-1058</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.39</theoretical-pi>
        <molecular-weight>149525.33</molecular-weight>
        <chromosome-location>13</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:55</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF071202</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3335173</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>782</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15439</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 4</synonym>
          <synonym>MOAT-B</synonym>
          <synonym>MRP/cMOAT-related ABC transporter</synonym>
          <synonym>MRP4</synonym>
          <synonym>Multi-specific organic anion transporter B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037136|Multidrug resistance-associated protein 4
MLPVYQEVKPNPLQDANLCSRVFFWWLNPLFKIGHKRRLEEDDMYSVLPEDRSQHLGEEL
QGFWDKEVLRAENDAQKPSLTRAIIKCYWKSYLVLGIFTLIEESAKVIQPIFLGKIINYF
ENYDPMDSVALNTAYAYATVLTFCTLILAILHHLYFYHVQCAGMRLRVAMCHMIYRKALR
LSNMAMGKTTTGQIVNLLSNDVNKFDQVTVFLHFLWAGPLQAIAVTALLWMEIGISCLAG
MAVLIILLPLQSCFGKLFSSLRSKTATFTDARIRTMNEVITGIRIIKMYAWEKSFSNLIT
NLRKKEISKILRSSCLRGMNLASFFSASKIIVFVTFTTYVLLGSVITASRVFVAVTLYGA
VRLTVTLFFPSAIERVSEAIVSIRRIQTFLLLDEISQRNRQLPSDGKKMVHVQDFTAFWD
KASETPTLQGLSFTVRPGELLAVVGPVGAGKSSLLSAVLGELAPSHGLVSVHGRIAYVSQ
QPWVFSGTLRSNILFGKKYEKERYEKVIKACALKKDLQLLEDGDLTVIGDRGTTLSGGQK
ARVNLARAVYQDADIYLLDDPLSAVDAEVSRHLFELCICQILHEKITILVTHQLQYLKAA
SQILILKDGKMVQKGTYTEFLKSGIDFGSLLKKDNEESEQPPVPGTPTLRNRTFSESSVW
SQQSSRPSLKDGALESQDTENVPVTLSEENRSEGKVGFQAYKNYFRAGAHWIVFIFLILL
NTAAQVAYVLQDWWLSYWANKQSMLNVTVNGGGNVTEKLDLNWYLGIYSGLTVATVLFGI
ARSLLVFYVLVNSSQTLHNKMFESILKAPVLFFDRNPIGRILNRFSKDIGHLDDLLPLTF
LDFIQTLLQVVGVVSVAVAVIPWIAIPLVPLGIIFIFLRRYFLETSRDVKRLESTTRSPV
FSHLSSSLQGLWTIRAYKAEERCQELFDAHQDLHSEAWFLFLTTSRWFAVRLDAICAMFV
IIVAFGSLILAKTLDAGQVGLALSYALTLMGMFQWCVRQSAEVENMMISVERVIEYTDLE
KEAPWEYQKRPPPAWPHEGVIIFDNVNFMYSPGGPLVLKHLTALIKSQEKVGIVGRTGAG
KSSLISALFRLSEPEGKIWIDKILTTEIGLHDLRKKMSIIPQEPVLFTGTMRKNLDPFNE
HTDEELWNALQEVQLKETIEDLPGKMDTELAESGSNFSVGQRQLVCLARAILRKNQILII
DEATANVDPRTDELIQKKIREKFAHCTVLTIAHRLNTIIDSDKIMVLDSGRLKEYDEPYV
LLQNKESLFYKMVQQLGKAEAAALTETAKQVYFKRNYPHIGHTDHMVTNTSNGQPSTLTI
FETAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010828|Multidrug resistance-associated protein 4 (ABCC4)
ATGCTGCCCGTGTACCAGGAGGTGAAGCCCAACCCGCTGCAGGACGCGAACCTCTGCTCA
CGCGTGTTCTTCTGGTGGCTCAATCCCTTGTTTAAAATTGGCCATAAACGGAGATTAGAG
GAAGATGATATGTATTCAGTGCTGCCAGAAGACCGCTCACAGCACCTTGGAGAGGAGTTG
CAAGGGTTCTGGGATAAAGAAGTTTTAAGAGCTGAGAATGACGCACAGAAGCCTTCTTTA
ACAAGAGCAATCATAAAGTGTTACTGGAAATCTTATTTAGTTTTGGGAATTTTTACGTTA
ATTGAGGAAAGTGCCAAAGTAATCCAGCCCATATTTTTGGGAAAAATTATTAATTATTTT
GAAAATTATGATCCCATGGATTCTGTGGCTTTGAACACAGCGTACGCCTATGCCACGGTG
CTGACTTTTTGCACGCTCATTTTGGCTATACTGCATCACTTATATTTTTATCACGTTCAG
TGTGCTGGGATGAGGTTACGAGTAGCCATGTGCCATATGATTTATCGGAAGGCACTTCGT
CTTAGTAACATGGCCATGGGGAAGACAACCACAGGCCAGATAGTCAATCTGCTGTCCAAT
GATGTGAACAAGTTTGATCAGGTGACAGTGTTCTTACACTTCCTGTGGGCAGGACCACTG
CAGGCGATTGCAGTGACTGCCCTACTCTGGATGGAGATAGGAATATCGTGCCTTGCTGGG
ATGGCAGTTCTAATCATTCTCCTGCCCTTGCAAAGCTGTTTTGGGAAGTTGTTCTCATCA
CTGAGGAGTAAAACTGCAACTTTCACGGATGCCAGGATCAGGACCATGAATGAAGTTATA
ACTGGTATAAGGATAATAAAAATGTACGCCTGGGAAAAGTCATTTTCAAATCTTATTACC
AATTTGAGAAAGAAGGAGATTTCCAAGATTCTGAGAAGTTCCTGCCTCAGAGGGATGAAT
TTGGCTTCATTTTTCAGTGCAAGCAAAATCATCGTGTTTGTGACCTTCACCACCTACGTG
CTCCTCGGCAGTGTGATCACAGCCAGCCGCGTGTTCGTGGCAGTGACGCTGTATGGGGCT
GTGCGGCTGACGGTTACCCTCTTCTTCCCCTCAGCCATTGAGAGGGTGTCAGAGGCAATC
GTCAGCATCCGAAGAATCCAGACCTTTTTGCTACTTGATGAGATATCACAGCGCAACCGT
CAGCTGCCGTCAGATGGTAAAAAGATGGTGCATGTGCAGGATTTTACTGCTTTTTGGGAT
AAGGCATCAGAGACCCCAACTCTACAAGGCCTTTCCTTTACTGTCAGACCTGGCGAATTG
TTAGCTGTGGTCGGCCCCGTGGGAGCAGGGAAGTCATCACTGTTAAGTGCCGTGCTCGGG
GAATTGGCCCCAAGTCACGGGCTGGTCAGCGTGCATGGAAGAATTGCCTATGTGTCTCAG
CAGCCCTGGGTGTTCTCGGGAACTCTGAGGAGTAATATTTTATTTGGGAAGAAATACGAA
AAGGAACGATATGAAAAAGTCATAAAGGCTTGTGCTCTGAAAAAGGATTTACAGCTGTTG
GAGGATGGTGATCTGACTGTGATAGGAGATCGGGGAACCACGCTGAGTGGAGGGCAGAAA
GCACGGGTAAACCTTGCAAGAGCAGTGTATCAAGATGCTGACATCTATCTCCTGGACGAT
CCTCTCAGTGCAGTAGATGCGGAAGTTAGCAGACACTTGTTCGAACTGTGTATTTGTCAA
ATTTTGCATGAGAAGATCACAATTTTAGTGACTCATCAGTTGCAGTACCTCAAAGCTGCA
AGTCAGATTCTGATATTGAAAGATGGTAAAATGGTGCAGAAGGGGACTTACACTGAGTTC
CTAAAATCTGGTATAGATTTTGGCTCCCTTTTAAAGAAGGATAATGAGGAAAGTGAACAA
CCTCCAGTTCCAGGAACTCCCACACTAAGGAATCGTACCTTCTCAGAGTCTTCGGTTTGG
TCTCAACAATCTTCTAGACCCTCCTTGAAAGATGGTGCTCTGGAGAGCCAAGATACAGAG
AATGTCCCAGTTACACTATCAGAGGAGAACCGTTCTGAAGGAAAAGTTGGTTTTCAGGCC
TATAAGAATTACTTCAGAGCTGGTGCTCACTGGATTGTCTTCATTTTCCTTATTCTCCTA
AACACTGCAGCTCAGGTTGCCTATGTGCTTCAAGATTGGTGGCTTTCATACTGGGCAAAC
AAACAAAGTATGCTAAATGTCACTGTAAATGGAGGAGGAAATGTAACCGAGAAGCTAGAT
CTTAACTGGTACTTAGGAATTTATTCAGGTTTAACTGTAGCTACCGTTCTTTTTGGCATA
GCAAGATCTCTATTGGTATTCTACGTCCTTGTTAACTCTTCACAAACTTTGCACAACAAA
ATGTTTGAGTCAATTCTGAAAGCTCCGGTATTATTCTTTGATAGAAATCCAATAGGAAGA
ATTTTAAATCGTTTCTCCAAAGACATTGGACACTTGGATGATTTGCTGCCGCTGACGTTT
TTAGATTTCATCCAGAGATGGGATCTCGCTGTGTTGTCCTGGCTGGTCTCAAACTCCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>15-hydroxyprostaglandin dehydrogenase (NAD+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="5">
      <id>BE0003655</id>
      <name>Solute carrier organic anion transporter family member 2A1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16468</ref-id>
            <pubmed-id>8787677</pubmed-id>
            <citation>Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.</citation>
          </article>
          <article>
            <ref-id>A16340</ref-id>
            <pubmed-id>7754369</pubmed-id>
            <citation>Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92959" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 2A1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.</specific-function>
        <gene-name>SLCO2A1</gene-name>
        <locus>3q21</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>33-52
72-92
99-123
168-196
216-236
255-279
322-343
364-387
392-415
519-541
551-576
611-629</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.95</theoretical-pi>
        <molecular-weight>70043.33</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10955</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U70867</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1617590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO2A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OATP2A1</synonym>
          <synonym>PGT</synonym>
          <synonym>Prostaglandin transporter</synonym>
          <synonym>SLC21A2</synonym>
          <synonym>Solute carrier family 21 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012541|Solute carrier organic anion transporter family member 2A1
MGLLPKLGASQGSDTSTSRAGRCARSVFGNIKVFVLCQGLLQLCQLLYSAYFKSSLTTIE
KRFGLSSSSSGLISSLNEISNAILIIFVSYFGSRVHRPRLIGIGGLFLAAGAFILTLPHF
LSEPYQYTLASTGNNSRLQAELCQKHWQDLPPSKCHSTTQNPQKETSSMWGLMVVAQLLA
GIGTVPIQPFGISYVDDFSEPSNSPLYISILFAISVFGPAFGYLLGSVMLQIFVDYGRVN
TAAVNLVPGDPRWIGAWWLGLLISSALLVLTSFPFFFFPRAMPIGAKRAPATADEARKLE
EAKSRGSLVDFIKRFPCIFLRLLMNSLFVLVVLAQCTFSSVIAGLSTFLNKFLEKQYGTS
AAYANFLIGAVNLPAAALGMLFGGILMKRFVFSLQAIPRIATTIITISMILCVPLFFMGC
STPTVAEVYPPSTSSSIHPQSPACRRDCSCPDSIFHPVCGDNGIEYLSPCHAGCSNINMS
SATSKQLIYLNCSCVTGGSASAKTGSCPVPCAHFLLPAIFLISFVSLIACISHNPLYMMV
LRVVNQEEKSFAIGVQFLLMRLLAWLPSPALYGLTIDHSCIRWNSLCLGRRGACAYYDND
ALRDRYLGLQMGYKALGMLLLCFISWRVKKNKEYNVQKAAGLI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012542|Solute carrier organic anion transporter family member 2A1 (SLCO2A1)
ATGGGGCTCCTGCCCAAGCTCGGCGCGTCCCAGGGCAGCGACACCTCTACTAGCCGAGCC
GGCCGCTGTGCCCGCTCGGTCTTCGGCAACATTAAGGTGTTTGTGCTCTGCCAAGGCCTC
CTGCAGCTCTGCCAACTCCTGTACAGCGCCTACTTCAAGAGCAGCCTCACCACCATTGAG
AAGCGCTTTGGGCTCTCCAGTTCTTCATCGGGTCTCATTTCCAGCTTGAATGAGATCAGC
AATGCCATCCTCATCATCTTTGTCAGCTACTTTGGCAGCCGGGTGCACCGTCCACGTCTG
ATTGGCATCGGAGGTCTCTTCCTGGCTGCAGGTGCCTTCATCCTCACCCTCCCACACTTC
CTCTCCGAGCCCTACCAGTACACCTTGGCCAGCACTGGGAACAACAGCCGCTTGCAGGCC
GAGCTCTGCCAGAAGCATTGGCAGGACCTGCCTCCCAGTAAGTGCCACAGCACCACCCAG
AACCCCCAGAAGGAGACCAGCAGCATGTGGGGCCTGATGGTGGTTGCCCAGCTGCTGGCT
GGCATCGGGACAGTGCCTATTCAGCCATTTGGGATCTCCTATGTGGATGACTTCTCAGAG
CCCAGCAACTCGCCCCTGTACATCTCCATCTTATTTGCCATCTCTGTATTTGGACCGGCT
TTCGGGTACCTGCTGGGCTCTGTCATGCTGCAGATCTTTGTGGACTATGGCAGGGTCAAC
ACAGCTGCAGTTAACTTGGTCCCGGGTGACCCCCGATGGATTGGAGCCTGGTGGCTAGGC
CTGCTCATTTCTTCAGCTTTATTGGTTCTCACCTCTTTCCCCTTTTTTTTCTTCCCTCGA
GCAATGCCCATAGGAGCAAAGAGGGCTCCTGCCACAGCAGATGAAGCAAGGAAGTTGGAG
GAGGCCAAGTCAAGAGGCTCCCTGGTGGATTTCATTAAACGGTTTCCATGCATCTTTCTG
AGGCTCCTGATGAACTCACTCTTCGTCCTGGTGGTCCTGGCCCAGTGCACCTTCTCCTCC
GTCATTGCTGGCCTCTCCACCTTCCTCAACAAGTTCCTGGAGAAGCAGTATGGCACCTCA
GCAGCCTATGCCAACTTCCTCATTGGTGCTGTGAACCTCCCTGCTGCAGCCTTGGGGATG
CTGTTTGGAGGAATCCTCATGAAGCGCTTTGTTTTCTCTCTACAAGCCATTCCCCGCATA
GCTACCACCATCATCACCATCTCCATGATCCTTTGTGTTCCTTTGTTCTTCATGGGATGC
TCCACCCCAACTGTGGCCGAAGTCTACCCCCCTAGCACATCAAGTTCTATACATCCGCAG
TCTCCTGCCTGCCGCAGGGACTGCTCGTGCCCAGATTCTATCTTCCACCCGGTCTGTGGA
GACAATGGAATCGAGTACCTCTCCCCTTGCCATGCCGGCTGCAGCAACATCAACATGAGC
TCTGCAACCTCCAAGCAACTGATCTATTTGAACTGCAGCTGTGTGACCGGGGGATCCGCT
TCAGCAAAGACAGGATCGTGCCCTGTCCCCTGTGCCCACTTCCTGCTCCCGGCCATCTTC
CTCATCTCCTTCGTGTCCCTGATAGCCTGCATCTCCCACAACCCCCTCTACATGATGGTT
CTGCGTGTGGTGAACCAGGAGGAAAAGTCATTTGCCATCGGGGTGCAGTTCTTGTTGATG
CGCTTGCTGGCCTGGCTGCCATCTCCAGCCCTCTATGGCCTCACCATTGACCACTCCTGC
ATCCGGTGGAACTCGCTGTGCTTGGGGAGGCGAGGGGCCTGCGCCTACTATGACAACGAT
GCTCTCCGAGACAGGTACCTGGGCCTGCAGATGGGCTACAAGGCGCTGGGCATGCTGCTG
CTTTGCTTCATCAGCTGGAGGGTGAAGAAGAACAAGGAGTACAACGTGCAGAAGGCGGCA
GGCCTCATCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="7">
      <id>BE0001066</id>
      <name>Solute carrier family 22 member 6</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33352</ref-id>
            <pubmed-id>19953504</pubmed-id>
            <citation>VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q4U2R8" source="Swiss-Prot">
        <name>Solute carrier family 22 member 6</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A6</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>10-30
136-156
165-187
191-213
225-245
249-269
338-358
369-389
396-416
426-446
456-475
485-505</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.78</theoretical-pi>
        <molecular-weight>61815.78</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>hROAT1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF057039</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3831566</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q4U2R8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT1</synonym>
          <synonym>hPAHT</synonym>
          <synonym>hROAT1</synonym>
          <synonym>OAT1</synonym>
          <synonym>Organic anion transporter 1</synonym>
          <synonym>PAH transporter</synonym>
          <synonym>PAHT</synonym>
          <synonym>Renal organic anion transporter 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037120|Solute carrier family 22 member 6
MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN
GGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI
VTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA
FAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV
AYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE
GAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL
QGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS
IVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE
LYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRWAPTQKEAGIYPRKGKQT
RQQQEHQKYMVPLQASAQEKNGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010747|Solute carrier family 22 member 6 (SLC22A6)
ATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG
GTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC
ACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC
GGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC
TTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG
GCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC
GTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG
TACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC
CGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC
TTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT
GGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC
TGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG
GCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC
TTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG
CTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA
GGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC
AAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC
TGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG
CAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT
GCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT
GCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC
ATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC
ATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG
GGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG
CTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC
ACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG
AGCAGGTGGGCCCCCACTCAGAAAGAAGCAGGGATATATCCCAGGAAAGGGAAACAGACG
CGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAG
AATGGACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-ketoglutarate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal tubular secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>